About Vicuron Pharmaceuticals
Vicuron Pharmaceuticals is a company based in King Of Prussia (United States) founded in 1995 was acquired by Durata Therapeutics in December 2009. Vicuron Pharmaceuticals operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, Freeline, Vir Biotechnology and Biological E, among others.
- Headquarter King Of Prussia, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Pfizer
& 1 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Vicuron Pharmaceuticals
Detailed funding history for Vicuron Pharmaceuticals
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Vicuron Pharmaceuticals
Vicuron Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Pfizer and Durata Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical products for treating multiple diseases are provided.
|
Locked | Locked | Locked | |
|
Novel antibiotics for infectious diseases are developed by the company.
|
Locked | Locked | Locked |
Investor details for Vicuron Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vicuron Pharmaceuticals
Investment portfolio details for Vicuron Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vicuron Pharmaceuticals
Detailed financials for Vicuron Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vicuron Pharmaceuticals Comparisons
Peer comparison for Vicuron Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vicuron Pharmaceuticals
Vicuron Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, Freeline, Vir Biotechnology and Biological E, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
AAV-based gene therapies for rare diseases are developed.
|
Detailed competitors of Vicuron Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vicuron Pharmaceuticals
Complete news archive for Vicuron Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vicuron Pharmaceuticals
Vicuron Pharmaceuticals was founded in 1995.
Vicuron Pharmaceuticals is headquartered in King Of Prussia, United States. It is registered at King Of Prussia, Pennsylvania, United States.
Vicuron Pharmaceuticals (formerly known as Versicor) is focused on the development of novel anti-infectives for both hospital-based and community-acquired infections. It had two products anidulafungin for fungal infections and dalbavancin for Gram-positive infections. It was initially acquired by Pfizer in June 2005 and received marketing rights for anidulafungin with the brand name Eraxis. In December 2009, Durata Therapeutics acquired Vicuron and its other drug candidate dalbavancin, which had generated Phase 3 results in acute bacterial infections of the skin and skin structures at the time of acquisition.
Vicuron Pharmaceuticals's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Vicuron Pharmaceuticals has 2 investors. Key investors include Pfizer, and Durata Therapeutics.